IPO-bound SG biotech startup Mirxes losses widen in 2023 despite revenue jump

IPO-bound SG biotech startup Mirxes losses widen in 2023 despite revenue jump

Mars W. Mosqueda Jr.

08 May, 2024

Printed by Unregistered user on Fri, 12 Dec 2025 21:39:07 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Biotech firm Mirxes said to be considering secondary listing on SGX

SG biotech startup Mirxes files for Hong Kong IPO after $50m Series D funding

Read more from Singapore

Hongkong Land to launch SG private real estate fund with $6.2b in AUM

SG’s Turn Capital acquires Taiwan fashion e-tailer FRND